{"id":960,"date":"2025-06-12T23:45:32","date_gmt":"2025-06-12T23:45:32","guid":{"rendered":"http:\/\/eurosoi.org\/?p=960"},"modified":"2025-06-12T23:45:32","modified_gmt":"2025-06-12T23:45:32","slug":"therefore-ebvs-role-in-nktcl-compared-to-b-cell-lymphomas-may-differ-following-initial-infection","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=960","title":{"rendered":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection"},"content":{"rendered":"<p>\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection. responses targeting all EBV life cycle stages were associated with NPC but limited to anti-early lytic stage for cHL. NPC and eBL were associated with IgG antibodies across the viral life cycle; cHL with antibodies in the early lytic, late lytic and glycoprotein stages; and NKTCL with antibodies in the latent, immediate early lytic and early lytic phases. EBNA3A, BBLF1, BDLF4, and BLRF2 IgG antibodies were associated with all malignancy types. == Asiaticoside Conclusion: == Our observed similarities and differences across four EBV-associated cancers may inform EBV-related oncogenesis. == Impact: == Understanding the comparative humoral immune response across EBV-related cancers may aid in identifying shared etiologic functions of EBV proteins and inform unique pathogenic processes for each Asiaticoside cancer. Keywords:Epstein-Barr computer virus, humoral immune response, nasopharyngeal carcinoma, lymphoma, antibodies == Introduction == Epstein-Barr computer virus (EBV) is a ubiquitous gamma-herpesvirus transmitted through oral secretions and found in over 90% of the global populace (1). In 1964, EBV became the first computer virus to be etiologically linked to human malignancy when it was discovered in tumor cells obtained from an African child with <a href=\"https:\/\/www.adooq.com\/asiaticoside.html\">Asiaticoside<\/a> Burkitt lymphoma (BL), and it was subsequently found to be epidemiologically associated with pediatric Burkitt lymphoma in Uganda (2). Since then, EBV has been implicated in both Hodgkin and non-Hodgkin lymphomas, as well as in epithelial cancers of the gastrointestinal tract and nasopharynx (1,3). EBV-related cancers exhibit unique ethnic and geographical distributions, although the reason for this remains unclear (4). EBV is unique since it causes cancers that affect unique cell types, including epithelial cells, lymphocytes, and mesenchymal cells (5). EBV contamination initiates in the oropharyngeal mucosal epithelium (6) and persists latently in B cells (7), with periodic phases of viral reactivation and lytic replication (7). Host factors such as age at primary contamination with EBV (8), smoking (9), and host genetics (10) might influence the levels of humoral immune (antibody) Asiaticoside responses against EBV. The molecular diversity (i.e., individual EBV antigen complexes) of the humoral immune response is thought to reflect host exposure to EBV proteins expressed during the different stages of viral latency, reactivation, and replication, which may differ among EBV disease entities linked to the pathogenic process (11). EBV contamination in cells occurs as latent or lytic contamination (12). Latent contamination occurs almost exclusively in B cells and entails expression of a limited set of EBV genes (EBNA1 and EBV-encoded small RNAs [EBERs]) to maintain viral episomes in the cells. Lytic contamination occurs in B cells and epithelial tissue, where the computer virus expresses many genes with a goal of generating viral progeny. Lytic replication entails temporal phases that are labeled as immediate early, early, and late cycles, during which specific EBV proteins are synthesized and released. Lytic replication ends when the infected cell bursts to release viral progeny that infect other cells in the same host or are transmitted to a new host, usually through saliva (13). Immunoglobulin A (IgA) antibodies to EBV are indicative of contamination at mucosal surfaces and wane relatively rapidly upon control of lytic contamination (14,15). In the context of tumorigenesis, these antibodies are believed to be enhanced by the reactivation of latent B cells that shed EBV along mucosal surfaces. In contrast to IgA, immunoglobulin G (IgG) Asiaticoside antibodies reflect systemic exposure to EBV contamination in circulating B cells. Since IgG antibody levels tend to <a href=\"http:\/\/people-press.org\/http:\/\/people-press.org\/files\/legacy-pdf\/652.pdf\"> IB1<\/a> wane very gradually over time, they reflect longer-term exposure. The molecular profiles associated with IgG and IgA responses to EBV in the context of diverse EBV-associated diseases have received relatively little scientific attention (11). Due to technological constraints, earlier studies focused on screening antibodies against only a limited number of EBV proteins or EBV-encoded antigen complexes (11,15). However, although only a few EBV-encoded proteins are expressed during viral latency, approximately 100 open reading frames are translated by EBV during a full lytic replication. To comprehensively assess the complexity of antibody responses against EBV, our group has developed a custom EBV array targeting 202 sequences representing 86 proteins expressed in the complete EBV proteome and all known splice variants (at the time of array printing). High coverage was achieved across the five EBV strains, with 97% of the predicted sequences for each train represented around the microarray at 99% homology. The protein array includes three synthetic EBNA1, VCAp18, and EAD multi-epitope peptides; 85% (169) of the 199 predicted sequences represented total transcripts from genes <1000bp in length, and 30 predicted sequences represented linear segments from eight EBV genes.\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection. responses targeting all EBV life cycle stages were associated with NPC but limited to anti-early lytic stage for cHL. NPC and eBL were associated with IgG antibodies across the viral life cycle; cHL with antibodies in <a href=\"https:\/\/eurosoi.org\/?p=960\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-960","post","type-post","status-publish","format-standard","hentry","category-m5-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=960\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection. responses targeting all EBV life cycle stages were associated with NPC but limited to anti-early lytic stage for cHL. NPC and eBL were associated with IgG antibodies across the viral life cycle; cHL with antibodies in Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=960\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-12T23:45:32+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection\",\"datePublished\":\"2025-06-12T23:45:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960\"},\"wordCount\":729,\"articleSection\":[\"M5 Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=960\",\"name\":\"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2025-06-12T23:45:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=960\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=960#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=960","og_locale":"en_US","og_type":"article","og_title":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection. responses targeting all EBV life cycle stages were associated with NPC but limited to anti-early lytic stage for cHL. NPC and eBL were associated with IgG antibodies across the viral life cycle; cHL with antibodies in Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=960","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2025-06-12T23:45:32+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=960#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=960"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection","datePublished":"2025-06-12T23:45:32+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=960"},"wordCount":729,"articleSection":["M5 Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=960","url":"https:\/\/eurosoi.org\/?p=960","name":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2025-06-12T23:45:32+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=960#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=960"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=960#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffTherefore, EBVs role in NKTCL compared to B-cell lymphomas may differ following initial infection"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=960"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/960\/revisions"}],"predecessor-version":[{"id":961,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/960\/revisions\/961"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}